Award information
2025 Shortlist
- BioVersys
- NewAmsterdam Pharma Company NV
- Oculis Holding AG
- Optima Health plc
- Vicore Pharma Holding AB
- Zealand Pharma
Criteria
This award recognises a significant capital market transaction during our period under review. The capital market transaction could be an IPO or a follow-on financing; it would be significant in scope and transformational in nature and would materially enhance the prospects for the business in the short, medium and long term.
In deciding the shortlist and eventual winner, the Voting Panel will take into account the amount raised, stock price performance and the quality of the share register.